Candriam Luxembourg S.C.A. decreased its stake in Omeros Corporation (NASDAQ:OMER) by 24.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,370 shares of the biopharmaceutical company’s stock after selling 27,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.19% of Omeros Corporation worth $1,620,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the company. National Asset Management Inc. purchased a new stake in shares of Omeros Corporation during the first quarter valued at approximately $158,000. Russell Investments Group Ltd. purchased a new stake in shares of Omeros Corporation during the first quarter valued at approximately $292,000. Highbridge Capital Management LLC purchased a new stake in shares of Omeros Corporation during the first quarter valued at approximately $330,000. American International Group Inc. raised its stake in shares of Omeros Corporation by 15.2% in the first quarter. American International Group Inc. now owns 24,521 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 3,232 shares during the period. Finally, Parametric Portfolio Associates LLC purchased a new stake in shares of Omeros Corporation during the first quarter valued at approximately $406,000. 45.11% of the stock is currently owned by institutional investors and hedge funds.
Shares of Omeros Corporation (NASDAQ OMER) opened at 23.45 on Friday. Omeros Corporation has a 1-year low of $7.20 and a 1-year high of $27.09. The company has a 50-day moving average price of $21.51 and a 200-day moving average price of $16.16. The stock’s market cap is $1.05 billion.
Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.12. The firm had revenue of $17.15 million during the quarter, compared to analyst estimates of $14.63 million. During the same period in the prior year, the business posted ($0.32) EPS. The company’s revenue for the quarter was up 71.5% on a year-over-year basis. On average, equities analysts expect that Omeros Corporation will post ($1.26) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Omeros Corporation (NASDAQ:OMER) Shares Sold by Candriam Luxembourg S.C.A.” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/08/12/omeros-corporation-nasdaqomer-shares-sold-by-candriam-luxembourg-s-c-a.html.
OMER has been the topic of several research analyst reports. Maxim Group set a $23.00 price target on Omeros Corporation and gave the stock a “buy” rating in a research note on Monday, May 22nd. BidaskClub raised Omeros Corporation from a “hold” rating to a “buy” rating in a research note on Sunday, June 18th. Cantor Fitzgerald set a $15.00 target price on Omeros Corporation and gave the company a “hold” rating in a research note on Tuesday, June 13th. ValuEngine raised Omeros Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research raised Omeros Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $32.80.
In related news, VP Michael A. Jacobsen sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $24.95, for a total value of $299,400.00. Following the completion of the transaction, the vice president now owns 19,500 shares of the company’s stock, valued at approximately $486,525. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael A. Jacobsen sold 24,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $21.20, for a total transaction of $508,800.00. Following the completion of the transaction, the vice president now directly owns 2,650 shares of the company’s stock, valued at approximately $56,180. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER).
What are top analysts saying about Omeros Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omeros Corporation and related companies.